Insmed, Inc. (INSM) Stock Price

INSMStock

$123.89−5.99%52W

Market Cap$27.06B

P/E—

PEG Ratio1.09

Div yield—

Beta0.82

INSM Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-29.20%

Price vs S&P 500 (4W)16.01%

PEG Ratio1.09

VGM Score50.65

Book Value / Share (Quarterly)$3.47

P/TBV (Annual)57.88x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)35.20%

Cash Flow / Share (Quarterly)$-3.70

Price vs S&P 500 (YTD)-40.72%

Gross Margin (TTM)83.46%

Net Profit Margin (TTM)-76.94%

EPS (TTM)$-4.10

10-Day Avg Trading Volume1.76M

EPS Excl Extra (TTM)$-4.10

Revenue Growth (5Y)29.83%

EPS (Annual)$-6.42

ROI (Annual)-87.04%

Gross Margin (Annual)79.73%

Net Profit Margin (5Y Avg)-226.84%

Cash / Share (Quarterly)$5.32

Revenue Growth QoQ (YoY)296.11%

ROA (Last FY)-56.38%

Revenue Growth TTM (YoY)185.76%

EBITD / Share (TTM)$-3.88

ROE (5Y Avg)-250.53%

Operating Margin (TTM)-73.89%

Cash Flow / Share (Annual)$-4.52

P/B Ratio37.56x

P/B Ratio (Quarterly)30.51x

Net Income / Employee (Annual)$-767,300

EV / Revenue (TTM)25.17x

Net Interest Coverage (TTM)-53.96x

ROA (TTM)-39.77%

EV / EBITDA (TTM)193.89x

EPS Incl Extra (Annual)$-6.42

Current Ratio (Annual)3.83x

Quick Ratio (Quarterly)3.14x

3-Month Avg Trading Volume3.48M

52-Week Price Return-5.99%

Revenue / Employee (TTM)$683,700

Tangible BV / Share (Quarterly)$3.04

P/S Ratio (Annual)46.92x

Asset Turnover (Annual)0.27x

52-Week High$212.75

Operating Margin (5Y Avg)-214.86%

EPS Excl Extra (Annual)$-6.42

CapEx CAGR (5Y)36.70%

Tangible BV CAGR (5Y)25.26%

26-Week Price Return-17.95%

Quick Ratio (Annual)3.35x

13-Week Price Return13.19%

Total Debt / Equity (Annual)0.98x

Current Ratio (Quarterly)3.72x

Enterprise Value$28.63B

Revenue / Share Growth (5Y)12.59%

Asset Turnover (TTM)0.52x

Book Value / Share Growth (5Y)3.40%

Revenue / Employee (Annual)$364,400

Inventory Turnover (Annual)1.07x

Pretax Margin (Annual)-209.71%

Cash / Share (Annual)$6.67

3-Month Return Std Dev79.61%

Gross Margin (5Y Avg)77.75%

Net Income / Employee (TTM)$-526,000

ROE (Last FY)-172.78%

Net Interest Coverage (Annual)-34.06x

EPS Basic Excl Extra (Annual)$-6.42

Receivables Turnover (TTM)8.42x

Total Debt / Equity (Quarterly)0.96x

EPS Incl Extra (TTM)$-4.10

Receivables Turnover (Annual)6.29x

ROI (TTM)-57.81%

P/S Ratio (TTM)25.01x

Pretax Margin (5Y Avg)-226.38%

Revenue / Share (Annual)$3.05

Tangible BV / Share (Annual)$2.99

Price vs S&P 500 (52W)-24.30%

Year-to-Date Return-28.76%

5-Day Price Return-3.49%

EPS Normalized (Annual)$-6.42

ROA (5Y Avg)-44.38%

Net Profit Margin (Annual)-210.54%

Month-to-Date Return25.74%

Cash Flow / Share (TTM)$-5.17

EBITD / Share (Annual)$-6.23

Operating Margin (Annual)-205.59%

LT Debt / Equity (Annual)0.95x

ROI (5Y Avg)-54.58%

LT Debt / Equity (Quarterly)0.93x

EPS Basic Excl Extra (TTM)$-4.10

P/TBV (Quarterly)34.80x

P/B Ratio (Annual)50.23x

Inventory Turnover (TTM)1.51x

Pretax Margin (TTM)-76.40%

Book Value / Share (Annual)$3.45

Price vs S&P 500 (13W)10.40%

Beta0.82x

Revenue / Share (TTM)$5.23

ROE (TTM)-111.26%

52-Week Low$90.39

vGradeF

gGradeA

mGradeC

vgmGradeC

INSM Earnings Surprise History

Q2 25-1.70est. -1.31

Q3 25-1.75est. -1.37

Q4 25-1.54est. -1.17

Q1 26-0.76est. -1.00

Q2 26-0.06est. -0.68

INSM Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.29

4.28

4.27

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
INSMInsmed, Inc.	F	A	C	$123.89
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$67.01

About Insmed, Inc.

Insmed is a biopharmaceutical company with two commercial respiratory products, Arikayce and Brinsupri, which generate revenue primarily from the United States. Its clinical pipeline spans respiratory, immunology, inflammation, and rare neurological disorders, including programs TPIP, INS1148, brensocatib, and INS1201. Pre-clinical research encompasses gene therapy, AI-driven protein engineering, and RNA end-joining technologies.